$SRNE The ADNAB™ platform was developed and exclusively licensed to Sorrento by the Mayo Clinic Clinical studies utilizing the ADNAB™ platform are ongoing at the Mayo Clinic; and are evaluating multiple platform-generated products in advanced-stage: endometrial cancer, ovarian cancer, angiosarcoma, and B-Cell lymphomas Study LS1681 is a Mayo Investigator-Initiated-Trial (IIT) for relapsed or refractory B-cell lymphomas; and is evaluating rituximab-ADNAB™ (nab-paclitaxel nanoparticles non-covalently coated with rituximab)1 Study MC1371 is a Mayo Investigator-Initiated-Trial (IIT) for various solid tumors; and has completed a dose escalation phase2. To date, 9 endometrial and ovarian cancer patients, that had failed at least one prior regimen containing…